drugset / Trial / NCT00443690

Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy

NCT00443690 ↗

Phase 3 Completed 480 enrolled Merck & Co., Inc. Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the effect of KW-3902IV, in addition to standard therapy, on the proportion of worsening heart failure and worsening renal function, and on the proportion of deaths or rehospitalizations for heart failure or worsening renal function, and to estimate and compare within-trial medical resource utilization and direct medical costs between subjects treated with KW 3902IV versus placebo.

Timeline

Start
2007-08
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject rolofylline Small molecule 30 mg Intravenous